Loading...
•
Jun 30, 2021
Collegium Q2 2021 Earnings Report
Collegium reported strong financial results, driven by the strength of its pain portfolio and growth of Xtampza ER market share, while net income was positively impacted by a one-time non-cash adjustment.
Key Takeaways
Collegium Pharmaceutical reported strong Q2 results, with net income of $72.8 million and adjusted EBITDA of $40.1 million. Xtampza ER market share grew to 31.5% of the oxycodone extended-release market in June 2021. The company updated its full-year 2021 product revenue guidance.
Xtampza ER market share grew to 31.5% of the oxycodone extended-release market in June 2021.
Net income for the quarter was $72.8 million, including a one-time non-cash adjustment of $62.6 million.
Adjusted EBITDA for the quarter was $40.1 million.
The company updated its full-year 2021 financial guidance for Xtampza ER and Nucynta Franchise revenues.
Revenue by Segment
Forward Guidance
The Company updates its full-year 2021 financial guidance for Xtampza ER Revenues and Nucynta Franchise Revenues.
Positive Outlook
- Nucynta Franchise Revenues updated from $185.0 to $195.0 million to $195.0 to $205.0 million
- Total Operating Expenses (Including Stock-Based Compensation) reaffirmed at $125.0 to $135.0 million
- Adjusted EBITDA (Excluding Stock-Based Compensation) reaffirmed at $170.0 to $180.0 million
- Nucynta Franchise prescriptions grew 0.5% over the first quarter of 2021
- Collegium remains in a strong financial position.
Challenges Ahead
- Collegium is not providing forward-looking guidance for its full-year 2021 U.S. GAAP net income (loss)
- Xtampza ER Revenues updated from $155.0 to $165.0 million to $140.0 to $150.0 million
- Ongoing impact of COVID-19
- Portfolio gross-to-net dynamics
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...